+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immunoassay Interference Blocker Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 245 Pages
  • December 2023
  • Region: Global
  • Fairfield Market Research
  • ID: 5916063
The worldwide market for immunoassay interference blockers is on the verge of substantial growth, with the market revenue estimated at US$ 280 Mn in 2024, and anticipated to reach a valuation of US$ 460 Mn by the end of 2031. This growth is driven by several key factors that underscore the increasing demand for immunoassay interference blocker kits and reagents.

Rising Prevalence of Chronic Diseases and Aging Population Fuel Market Demand

One of the primary drivers of the immunoassay interference blocker market is the escalating frequency of chronic diseases worldwide, coupled with the aging global population. As the burden of chronic illnesses continues to rise, there is a growing need for accurate diagnostic tests and tools, leading to an increased demand for immunoassay interference blocker kits.

Collaborative R&D Efforts Boost Product Development

The market for immunoassay interference blockers is also benefiting from collaborative research and development initiatives between manufacturers and researchers. These partnerships have led to the creation of newer and more effective immunoassay interference blockers, further expanding the market's potential.

Academic and Biotechnology Institutions as Key Consumers

Academic institutions, research organizations, and biotechnology enterprises have emerged as prominent consumers of immunoassay interference blockers. This trend has opened up previously untapped product niches, providing manufacturers with new growth opportunities.

Innovations in Disease Diagnosis Drive Market Growth

Manufacturers in the immunoassay interference blocker industry are working together to develop advanced instruments, kits, and materials capable of quickly identifying a wide range of chronic diseases. These innovations are expected to play a pivotal role in defining disease progression, including cancer and various infectious and viral disorders, as well as predicting patient survival rates. This presents a significant growth opportunity for the industry, particularly in the field of molecular diagnostics.

Factors Influencing Market Growth:

1. Economic Boom in Asia Pacific Countries Offers Great Revenue Opportunity: The Asia Pacific region, including countries like India, China, Japan, and Indonesia, is witnessing a rapid increase in healthcare demand due to continuous economic growth. Rising per capita income and healthcare expenditures are contributing to the expansion of the healthcare sector in the region.

2. Low FDA Approvals Impact Global Growth: Slow approval processes and limited clinical evidence supporting the use of immunoassay interference blocker kits have negatively impacted the market's growth. Additionally, less generous reimbursement policies have hindered market progress.

3. Booming U.S. Market with Vast Biotechnology Presence: The presence of numerous biotechnology companies in the United States is driving market growth in the country.

4. Germany: A Lucrative Market with an Aging Population and High Prevalence of Chronic Diseases: The aging population and a high prevalence of chronic diseases make Germany a potentially lucrative market for immunoassay interference blocker manufacturers.

5. Japan Emerges as a Prominent Market with a Vast Patient Pool Suffering from Eye Disorders: Japan's significant patient pool suffering from eye disorders is making it an emerging market for immunoassay interference blocker products.

Competitive Landscape:

Manufacturers are focused on diversifying their product lines by introducing innovative products and securing approvals from governmental agencies. Leading providers of immunoassay blockers are actively engaged in strategic product development and expansion through partnerships to enhance their market position.

Key Companies’ Profiled:

  • Abcam plc
  • AMS Biotechnology (Europe) Limited
  • Aviva Systems Biology Corporation
  • Bio-Rad Laboratories, Inc.
  • Meridian Bioscience, Inc.
  • Roche Diagnostics GmbH
  • Rockland Immunochemicals, Inc.
  • Scantibodies Laboratory, Inc.
  • Thermo Fisher Scientific Inc

Market Segmentation

Product:

  • Antibody Interference Blockers
  • Human Serum Derived Blockers
  • Animal Serum Derived Blockers
  • Human Immunoglobulin Blockers
  • Animal Monoclonal Antibody IgG Blockers
  • Animal Polyclonal Antibody IgG Blockers
  • Heterophile Blocking Reagents
  • Others
  • Detection Interference Blockers
  • Enzyme Blockers
  • Alkaline Phosphatase Blockers
  • β-Galactosidase Blockers
  • Others
  • Surface Interference Blockers
  • Bovine Serum Albumin Blockers
  • BSA Fraction V blockers
  • Poly BSA Blockers
  • Solid Phase Blocking Buffers
  • Polymeric Blockers

Application:

  • Sandwich Immunoassay
  • Antibody Capture Assays
  • Competitive ELISA
  • Others

End User:

  • Biotechnology Companies
  • Contract Research Organizations
  • Academic and Research Institutes
  • Molecular Diagnostics Companies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Immunoassay Interference Blocker Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Immunoassay Interference Blocker Market Outlook, 2018 - 2031
3.1. Global Immunoassay Interference Blocker Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Antibody Interference Blockers
3.1.1.1.1. Human Serum Derived Blockers
3.1.1.1.2. Animal Serum Derived Blockers
3.1.1.1.3. Human Immunoglobulin Blockers
3.1.1.1.4. Animal Monoclonal Antibody IgG Blockers
3.1.1.1.5. Animal Polyclonal Antibody IgG Blockers
3.1.1.1.6. Heterophile Blocking Reagents
3.1.1.1.7. Others
3.1.1.2. Detection Interference Blockers
3.1.1.2.1. Enzyme Blockers
3.1.1.2.2. Alkaline Phosphatase Blockers
3.1.1.2.3. ß-Galactosidase Blockers
3.1.1.2.4. Others
3.1.1.3. Surface Interference Blockers
3.1.1.3.1. Bovine Serum Albumin Blockers
3.1.1.3.2. BSA Fraction V blockers
3.1.1.3.3. Poly BSA Blockers
3.1.1.3.4. Solid Phase Blocking Buffers
3.1.1.3.5. Polymeric Blockers
3.2. Global Immunoassay Interference Blocker Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Sandwich Immunoassay
3.2.1.2. Antibody Capture Assays
3.2.1.3. Competitive ELISA
3.2.1.4. Others
3.3. Global Immunoassay Interference Blocker Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Biotechnology Companies
3.3.1.2. Contract Research Organizations
3.3.1.3. Academic and Research Institutes
3.3.1.4. Molecular Diagnostics Companies
3.4. Global Immunoassay Interference Blocker Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Immunoassay Interference Blocker Market Outlook, 2018 - 2031
4.1. North America Immunoassay Interference Blocker Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Antibody Interference Blockers
4.1.1.1.1. Human Serum Derived Blockers
4.1.1.1.2. Animal Serum Derived Blockers
4.1.1.1.3. Human Immunoglobulin Blockers
4.1.1.1.4. Animal Monoclonal Antibody IgG Blockers
4.1.1.1.5. Animal Polyclonal Antibody IgG Blockers
4.1.1.1.6. Heterophile Blocking Reagents
4.1.1.1.7. Others
4.1.1.2. Detection Interference Blockers
4.1.1.2.1. Enzyme Blockers
4.1.1.2.2. Alkaline Phosphatase Blockers
4.1.1.2.3. ß-Galactosidase Blockers
4.1.1.2.4. Others
4.1.1.3. Surface Interference Blockers
4.1.1.3.1. Bovine Serum Albumin Blockers
4.1.1.3.2. BSA Fraction V blockers
4.1.1.3.3. Poly BSA Blockers
4.1.1.3.4. Solid Phase Blocking Buffers
4.1.1.3.5. Polymeric Blockers
4.2. North America Immunoassay Interference Blocker Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Sandwich Immunoassay
4.2.1.2. Antibody Capture Assays
4.2.1.3. Competitive ELISA
4.2.1.4. Others
4.3. North America Immunoassay Interference Blocker Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Biotechnology Companies
4.3.1.2. Contract Research Organizations
4.3.1.3. Academic and Research Institutes
4.3.1.4. Molecular Diagnostics Companies
4.4. North America Immunoassay Interference Blocker Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
4.4.1.2. U.S. Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
4.4.1.3. U.S. Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
4.4.1.4. Canada Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
4.4.1.5. Canada Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
4.4.1.6. Canada Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Immunoassay Interference Blocker Market Outlook, 2018 - 2031
5.1. Europe Immunoassay Interference Blocker Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Antibody Interference Blockers
5.1.1.1.1. Human Serum Derived Blockers
5.1.1.1.2. Animal Serum Derived Blockers
5.1.1.1.3. Human Immunoglobulin Blockers
5.1.1.1.4. Animal Monoclonal Antibody IgG Blockers
5.1.1.1.5. Animal Polyclonal Antibody IgG Blockers
5.1.1.1.6. Heterophile Blocking Reagents
5.1.1.1.7. Others
5.1.1.2. Detection Interference Blockers
5.1.1.2.1. Enzyme Blockers
5.1.1.2.2. Alkaline Phosphatase Blockers
5.1.1.2.3. ß-Galactosidase Blockers
5.1.1.2.4. Others
5.1.1.3. Surface Interference Blockers
5.1.1.3.1. Bovine Serum Albumin Blockers
5.1.1.3.2. BSA Fraction V blockers
5.1.1.3.3. Poly BSA Blockers
5.1.1.3.4. Solid Phase Blocking Buffers
5.1.1.3.5. Polymeric Blockers
5.2. Europe Immunoassay Interference Blocker Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Sandwich Immunoassay
5.2.1.2. Antibody Capture Assays
5.2.1.3. Competitive ELISA
5.2.1.4. Others
5.3. Europe Immunoassay Interference Blocker Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Biotechnology Companies
5.3.1.2. Contract Research Organizations
5.3.1.3. Academic and Research Institutes
5.3.1.4. Molecular Diagnostics Companies
5.4. Europe Immunoassay Interference Blocker Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.2. Germany Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.3. Germany Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
5.4.1.4. U.K. Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.5. U.K. Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.6. U.K. Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
5.4.1.7. France Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.8. France Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.9. France Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
5.4.1.10. Italy Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.11. Italy Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.12. Italy Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
5.4.1.13. Turkey Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.14. Turkey Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.15. Turkey Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
5.4.1.16. Russia Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.17. Russia Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.18. Russia Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
5.4.1.19. Rest of Europe Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.20. Rest of Europe Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.21. Rest of Europe Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Immunoassay Interference Blocker Market Outlook, 2018 - 2031
6.1. Asia Pacific Immunoassay Interference Blocker Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Antibody Interference Blockers
6.1.1.1.1. Human Serum Derived Blockers
6.1.1.1.2. Animal Serum Derived Blockers
6.1.1.1.3. Human Immunoglobulin Blockers
6.1.1.1.4. Animal Monoclonal Antibody IgG Blockers
6.1.1.1.5. Animal Polyclonal Antibody IgG Blockers
6.1.1.1.6. Heterophile Blocking Reagents
6.1.1.1.7. Others
6.1.1.2. Detection Interference Blockers
6.1.1.2.1. Enzyme Blockers
6.1.1.2.2. Alkaline Phosphatase Blockers
6.1.1.2.3. ß-Galactosidase Blockers
6.1.1.2.4. Others
6.1.1.3. Surface Interference Blockers
6.1.1.3.1. Bovine Serum Albumin Blockers
6.1.1.3.2. BSA Fraction V blockers
6.1.1.3.3. Poly BSA Blockers
6.1.1.3.4. Solid Phase Blocking Buffers
6.1.1.3.5. Polymeric Blockers
6.2. Asia Pacific Immunoassay Interference Blocker Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Sandwich Immunoassay
6.2.1.2. Antibody Capture Assays
6.2.1.3. Competitive ELISA
6.2.1.4. Others
6.3. Asia Pacific Immunoassay Interference Blocker Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Biotechnology Companies
6.3.1.2. Contract Research Organizations
6.3.1.3. Academic and Research Institutes
6.3.1.4. Molecular Diagnostics Companies
6.4. Asia Pacific Immunoassay Interference Blocker Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.2. China Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.3. China Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
6.4.1.4. Japan Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.5. Japan Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.6. Japan Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
6.4.1.7. South Korea Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.8. South Korea Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.9. South Korea Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
6.4.1.10. India Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.11. India Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.12. India Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
6.4.1.13. Southeast Asia Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.14. Southeast Asia Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.15. Southeast Asia Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Immunoassay Interference Blocker Market Outlook, 2018 - 2031
7.1. Latin America Immunoassay Interference Blocker Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Antibody Interference Blockers
7.1.1.1.1. Human Serum Derived Blockers
7.1.1.1.2. Animal Serum Derived Blockers
7.1.1.1.3. Human Immunoglobulin Blockers
7.1.1.1.4. Animal Monoclonal Antibody IgG Blockers
7.1.1.1.5. Animal Polyclonal Antibody IgG Blockers
7.1.1.1.6. Heterophile Blocking Reagents
7.1.1.1.7. Others
7.1.1.2. Detection Interference Blockers
7.1.1.2.1. Enzyme Blockers
7.1.1.2.2. Alkaline Phosphatase Blockers
7.1.1.2.3. ß-Galactosidase Blockers
7.1.1.2.4. Others
7.1.1.3. Surface Interference Blockers
7.1.1.3.1. Bovine Serum Albumin Blockers
7.1.1.3.2. BSA Fraction V blockers
7.1.1.3.3. Poly BSA Blockers
7.1.1.3.4. Solid Phase Blocking Buffers
7.1.1.3.5. Polymeric Blockers
7.2. Latin America Immunoassay Interference Blocker Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Sandwich Immunoassay
7.2.1.2. Antibody Capture Assays
7.2.1.3. Competitive ELISA
7.2.1.4. Others
7.3. Latin America Immunoassay Interference Blocker Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Biotechnology Companies
7.3.1.2. Contract Research Organizations
7.3.1.3. Academic and Research Institutes
7.3.1.4. Molecular Diagnostics Companies
7.4. Latin America Immunoassay Interference Blocker Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
7.4.1.2. Brazil Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
7.4.1.3. Brazil Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
7.4.1.4. Mexico Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
7.4.1.5. Mexico Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
7.4.1.6. Mexico Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
7.4.1.7. Argentina Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
7.4.1.8. Argentina Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
7.4.1.9. Argentina Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
7.4.1.10. Rest of Latin America Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
7.4.1.11. Rest of Latin America Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
7.4.1.12. Rest of Latin America Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Immunoassay Interference Blocker Market Outlook, 2018 - 2031
8.1. Middle East & Africa Immunoassay Interference Blocker Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Antibody Interference Blockers
8.1.1.1.1. Human Serum Derived Blockers
8.1.1.1.2. Animal Serum Derived Blockers
8.1.1.1.3. Human Immunoglobulin Blockers
8.1.1.1.4. Animal Monoclonal Antibody IgG Blockers
8.1.1.1.5. Animal Polyclonal Antibody IgG Blockers
8.1.1.1.6. Heterophile Blocking Reagents
8.1.1.1.7. Others
8.1.1.2. Detection Interference Blockers
8.1.1.2.1. Enzyme Blockers
8.1.1.2.2. Alkaline Phosphatase Blockers
8.1.1.2.3. ß-Galactosidase Blockers
8.1.1.2.4. Others
8.1.1.3. Surface Interference Blockers
8.1.1.3.1. Bovine Serum Albumin Blockers
8.1.1.3.2. BSA Fraction V blockers
8.1.1.3.3. Poly BSA Blockers
8.1.1.3.4. Solid Phase Blocking Buffers
8.1.1.3.5. Polymeric Blockers
8.2. Middle East & Africa Immunoassay Interference Blocker Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Sandwich Immunoassay
8.2.1.2. Antibody Capture Assays
8.2.1.3. Competitive ELISA
8.2.1.4. Others
8.3. Middle East & Africa Immunoassay Interference Blocker Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Biotechnology Companies
8.3.1.2. Contract Research Organizations
8.3.1.3. Academic and Research Institutes
8.3.1.4. Molecular Diagnostics Companies
8.4. Middle East & Africa Immunoassay Interference Blocker Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
8.4.1.2. GCC Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.3. GCC Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
8.4.1.4. South Africa Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
8.4.1.5. South Africa Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.6. South Africa Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
8.4.1.7. Egypt Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
8.4.1.8. Egypt Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.9. Egypt Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
8.4.1.10. Nigeria Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
8.4.1.11. Nigeria Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.12. Nigeria Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Immunoassay Interference Blocker Market by Product, Value (US$ Mn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Immunoassay Interference Blocker Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Immunoassay Interference Blocker Market End User, Value (US$ Mn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Product vs End User Heatmap
9.2. Manufacturer vs End User Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Abcam plc
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. AMS Biotechnology (Europe) Limited
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Aviva Systems Biology Corporation
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Bio-Rad Laboratories, Inc.
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Meridian Bioscience, Inc.
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Roche Diagnostics GmbH
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Rockland Immunochemicals, Inc.
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Scantibodies Laboratory, Inc.
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Thermo Fisher Scientific Inc
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Thermo Fisher Scientific Inc
  • Abcam plc
  • AMS Biotechnology (Europe) Limited
  • Aviva Systems Biology Corporation
  • Bio-Rad Laboratories, Inc.
  • Meridian Bioscience, Inc.
  • Roche Diagnostics GmbH
  • Rockland Immunochemicals, Inc.
  • Scantibodies Laboratory, Inc.

Methodology

Loading
LOADING...